Description: Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
Home Page: www.kuros.ch
Wagistrasse 25
Schlieren,
8952
Switzerland
Phone:
41 44 733 4747
Officers
| Name | Title |
|---|---|
| Prof. Joost D. de Bruijn B.S., B.Sc. Ph.D., Ph.D. | CEO & Director |
| Mr. Michael Grau M.B.A., MBA | Chief Financial Officer |
| Mr. Christopher T. Fair | Chief Operating Officer |
| Dr. Katherine Sage D.O., M.S. | VP of Medical Affairs & Director of Scientific Affairs |
| Dr. Oliver P. Kronenberg | Sr. Legal Counsel |
| Dr. Charlie Campion | Sr. VP of Marketing & International Sales |
| Dr. Alistair Irvine Ph.D. | Chief Bus. Officer |
| Dr. Philippe Saudan Ph.D. | Chief Devel. Officer |
| Mr. John Griffin | Sr. VP & Pres of US Sales |
| Ms. Florence Barrere de Groot Ph.D. | Head of Devel. |
Exchange: SW
Country: CH : Switzerland
Currency: Swiss Franc (CHF)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7888 |
| Price-to-Sales TTM: | 3.6291 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 64 |